Table 5 Clinical outcomes of patients with an eGFR of less than 30 mL/min/1.73m2 (5-day course of remdesivir treatment)
Unmatched cohort | Propensity score-matched cohort | |||||
|---|---|---|---|---|---|---|
Remdesivir (N = 211) | Standard care (N = 206) | P value | Remdesivir (N = 50) | Standard care (N = 50) | P value | |
Day 5 laboratory result, median (IQR) | ||||||
Creatinine (mg/dL) | 2.6 (1.7–6.6) | 2.9 (1.8–6.3) | 0.431 | 3.1 (1.7–7.4) | 2.9 (1.7–6) | 0.817 |
AST (IU/L) | 28 (18–41.5) | 24 (18–35) | 0.141 | 27 (17–37.5) | 23 (16.5–33.5) | 0.574 |
ALT (IU/L) | 20 (13–33) | 16 (11–28) | 0.025 | 18 (11.5–23) | 16 (12–24.5) | 0.957 |
eGFR (mL/min/1.73m2) | 22 (7–37.5) | 19.5 (7–33) | 0.233 | 18.8 (6.8–35.3) | 18 (7–34.3) | 0.839 |
New dialysis in those not receiving dialysis at baseline | 13 (6.2) | 5 (2.4) | 0.061 | 0 (0) | 1 (2) | 0.999 |
Oxygen requirement during hospitalization, N (%) | 185 (87.7) | 114 (55.3) | < 0.001 | 41 (82) | 35 (70) | 0.160 |
No oxygen requirement | 26 (12.3) | 92 (44.7) | < 0.001 | 9 (18) | 15 (30) | 0.049 |
Nasal cannula | 131 (62.1) | 57 (27.7) | 28 (56) | 16 (32) | ||
Facial mask | 8 (3.8) | 11 (5.3) | 2 (4) | 3 (6) | ||
High flow nasal cannula | 35 (16.6) | 33 (16.0) | 5 (10) | 13 (26) | ||
Invasive ventilation | 11 (5.2) | 12 (5.8) | 6 (12) | 3 (6) | ||
ECMO | 0 (0) | 1 (0.5) | 0 (0) | 0 (0) | ||
Progression of oxygen supplya | 83 (39.3) | 64 (31.1) | 0.077 | 16 (32) | 17 (34) | 0.832 |
Median time to progression of oxygen supply, days (IQR) | 1 (1–2) | 1 (1–3) | 0.619 | 1 (1–2) | 1 (1–2) | 0.688 |
Disease severity scores on ordinal scale | ||||||
Progression of ordinal score during hospitalization | 0 (-2–2) | 0 (0–1) | 0.071 | 1 (-3–2) | 1 (0–2) | 0.602 |
Ordinal score at day 21 or discharge, median (IQR) | 2 (1–6) | 1 (1–2) | 0.159 | 2 (1–8) | 1 (1–2) | 0.221 |
Hospitalization | ||||||
Median duration of hospitalization (IQR) | 12 (7–19) | 10 (7–16) | 0.034 | 11 (8–17.3) | 11.5 (8–17.5) | 0.994 |
Median duration of hospitalization among those who did not die or transfer (IQR) | 11 (8–16.5) | 11 (8–14) | 0.321 | 10 (8–12) | 11 (8–16.5) | 0.097 |
Mortalityb | 46/191 (24.1) | 42/197 (21.3) | 0.516 | 13/48 (27.1) | 6/47 (12.8) | 0.081 |
Mortality through day 21 | 37/191 (19.4) | 36/197 (18.3) | 0.782 | 10/48 (20.8) | 5/47 (10.6) | 0.173 |
COVID-19 attributable mortality through day 21 | 33/191 (17.3) | 31/197 (15.7) | 0.683 | 8/48 (16.7) | 4/47 (8.5) | 0.232 |
Mortality through day 28 | 41/191 (21.5) | 40/197 (20.3) | 0.778 | 11/48 (22.9) | 6/47 (12.8) | 0.197 |
COVID-19 attributable mortality through day 28 | 37/191 (19.4) | 34/197 (17.3) | 0.590 | 9/48 (18.8) | 5/47 (10.6) | 0.265 |